COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,731 Articles (22,502 medRxiv, 8,229 bioRxiv)

Most recent first Previous |  Page 8: Articles 71-80  | Next

Exploring Novel Kinetics of Automated H2O2 Nebulization: A Breakthrough in SARS-CoV-2 Elimination.
Solano-Parada, J., Sanchez-Martinez, J. A., Gomez-Hernandez, B. C., Barriga, M., Garcia-Velasco, P., Fernandez, A., Cornet-Gomez, A., Osuna Carrillo, A., Fabregas, R., Morales-Garcia, C.
10.1101/2025.06.04.25327212 — Posted: 2025-06-07
Therapeutic Potential of Transcranial Magnetic Stimulation (TMS) in Long COVID: Protocol for a Systematic Review and Meta-Analysis
Sanal-Hayes, N., Slade, K., Mclaughlin, M., Berry, E., Swift, E., Hayes, L. D.
10.1101/2025.06.05.25329096 — Posted: 2025-06-06
Telehealth usage patterns among pediatric neurology patients during and after the COVID-19 pandemic in Washington state
Ch'en, P. Y., Barry, D., Morgan, L. A., Wainwright, M. S., Patel, P. B.
10.1101/2025.06.04.25329018 — Posted: 2025-06-06
Systemic immune profile in hospitalized patients with tuberculosis and Covid-19
Ridolfi, F., Guimaraes, S. S., Araujo-Pereira, M., Bemfica, N. S., De Oliveira, Q. M., Xavier, M. S., Roma, E. H., SantAnna, F. M., De Andrade, A. M., Figueiredo, M. C., Sterling, T. R., Gordhan, B. G., Kana, B. D., Andrade, B. B., Gomes-Silva, A., Rolla, V. C., Associative BRICS Research in Covid-19 and TB (ABRICOT) Research Group
10.1101/2025.06.05.25329097 — Posted: 2025-06-06
In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
Yang, Y., Qiao, L., Jiang, Y., Wang, Z., Zhang, D., Buratto, D., Huang, L., Zhou, R.
10.1101/2025.06.04.657802 — Posted: 2025-06-06
Designing a broad-spectrum four-helix bundle targeting different strains of SARS-CoV-2 Spike Receptor Binding Domains with ACE2-like binding interface
Nie, Q., Zhou, Y., Yin, H., Chen, K., Tang, J., Zhang, J. Z. H., Zhan, J., Qi, J., Li, W., Zhang, C.
10.1101/2025.06.04.657798 — Posted: 2025-06-06
Rationally Designed, ACE2 Mimetic Binder to the SARS Cov-2 Associated Spike Protein for COVID-19 Therapeutics and Beyond
Peters, M. H., Pei, X. Y.
10.1101/2025.06.05.658001 — Posted: 2025-06-06
Olfactory cleft obstruction in post-COVID-19 olfactory disorder: CT Comparison with post-viral cases
Tanaka, H., Mori, E., Kishimoto, Y., Yonezawa, N., Sekine, R., Nagai, M., Tei, M., Otori, N.
10.1101/2025.06.04.25328964 — Posted: 2025-06-05
Work absenteeism across economic activity sectors and its association with COVID-19-like illness prevalence in the Netherlands, 2020-2023
Korthals Altes, H., van de Kassteele, J., Wisse, B., Xiridou, M., van Hoek, A. J., Wallinga, J.
10.1101/2025.05.26.25328340 — Posted: 2025-06-04
CellVoyager: AI CompBio Agent Generates New Insights by Autonomously Analyzing Biological Data
Alber, S., Chen, B., Sun, E., Isakova, A., Wilk, A. J., Zou, J.
10.1101/2025.06.03.657517 — Posted: 2025-06-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).